Should the Phase 3 trial prove successful, ganaplacide/lumefantrine could be an alternative to artemisinin-based treatments, which are being increasingly challenged by resistant strains of malaria. Indeed, as the world faces emerging resistance to current malaria treatments, new drugs are critical.
